Support low-grade serous ovarian cancer in Australia
Since 2019, the Low-Grade Serous Ovarian Cancer Initiative has proudly partnered with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) through WomenCan, ANZGOG’s fundraising arm.
ANZGOG, the leading clinical trials organisation for gynaecological cancers in Australia and New Zealand, is dedicated to advancing research on low-grade serous ovarian cancer (LGSOC).
Together, our fundraising and donation efforts are driving significant advancements in LGSOC research. As ANZGOG and WomenCan focus on all gynaecological cancers, we encourage you to direct your support through the links on this page to ensure your donation or fundraising is added to ANZGOG’s LGSOC-specific research fund.
Research highlights from Australia
Support Australian researchers as they search for new treatments for LGSOC.
ANZGOG’s LGSOC research achievements include:
- Paragon I – the first prospective clinical trial of hormonal therapy for low-grade serous ovarian cancer.
- Paragon II – an ongoing trial investigating letrozole and ribociclib.
- Funding awarded to Dr Tania Moujaber to explore the potential of MEK and CDK4/6 as a combination treatment for LGSOC.
- ANZGOG Research Advisory Committee member Professor Anna deFazio is leading a project to molecularly characterise LGSOC and identify novel treatment targets in collaboration with the ICLC.
WomenCan
WomenCan is the fundraising arm of our Australian research and charity partner, the Australia New Zealand Gynaecological Oncology Group (ANZGOG).
Their mission is to engage the community in funding research driven by evidence of need, with the ambition to change practice, improve outcomes, and provide hope.
At the LGSOC Initiative, we share this passion for research and have established a dedicated pathway to ensure that anyone interested in raising funds for LGSOC research has a way to do so. Get involved today!
Fundraise or donate today to help us fund transformational LGSOC research!
LGSOC hero: Kristen Larsen
In 2013, at just 21 years old, Kristen Larsen was diagnosed with Stage 3C low-grade serous ovarian cancer. The diagnosis was shocking; Kristen had no family history of cancer and experienced minimal symptoms before her diagnosis.
Kristen underwent an 11-hour debulking surgery and six rounds of aggressive chemotherapy, achieving NED (no evidence of disease). Unfortunately, the cancer recurred just 12 months later.
Despite numerous treatments to slow progression and stabilise her tumours, Kristen’s cancer continued to progress. Each treatment extended her life, and she was profoundly grateful for the advancements in research that made this possible.
Determined to make a difference, Kristen dedicated the six years following her diagnosis to raising awareness and funds for LGSOC. She passionately embraced her role as an advocate, sharing her story globally, speaking at events, and leading numerous campaigns. Her relentless efforts raised millions for ovarian cancer charities.
On December 9, 2019, Kristen passed away at the age of 27. Shortly before her death, she established her ‘Living Legacy’ page to inspire ongoing donations and fundraising in her honour. Kristen’s wish was for her story to continue making a difference in ovarian cancer research.
In her memory, Kristen’s friends and family are committed to fundraising for LGSOC research to improve survival rates and offer hope to other women.
I dedicated my years here on earth to raising awareness and funds for cancer research. Women like me, with low-grade ovarian cancer, need disease specific research and this is extremely difficult to compete for funding for.
Kristen
Recent news and updates from Australia
